SAR
Side Effects and Drug Design
1st Edition
Published on 10. September 2020
384 pages
978-1-000-14689-9 (ISBN)
Description
This book focuses on the quantitative structure-activity relationship of the disposition and activities of various pharmacological groups. It presents a systematic approach for linking different side effect of drugs to their molecular structure and physiochemical properties.
More details
Series
Edition
1. Auflage
Language
English
Place of publication
London
United Kingdom
Publishing group
Taylor & Francis Ltd
Target group
Professional and scholarly
Product notice
Reflowable
ISBN-13
978-1-000-14689-9 (9781000146899)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Book
03/1987
1st Edition
CRC Press
€173.32
Shipment within 15-20 days
Person
Eric J. Lien is Professor of Pharmacy and Biomedical Chemistry at the University of Southern California School of Pharmacy, Los Angeles. Dr. Lien is the author of SAR Analysis and Anticancer Chinese Drugs and Related Plants and U.S. New Drug Digest, 1980-86, as well as over 160 scientific papers and chapters in pharmaceutical textbooks. He is on the editorial boards of Journal of Clinical and Hospital Pharmacy and Oriental Healing Arts International Bulletin. A member of many scientific and professional societies, Dr. Lien also serves as a consultant to the National Institutes of Health. He received the B.S. (1960) degree in pharmacy from the School of Pharmacy, College of Medicine, National Taiwan University, Ph.D. (1966) degree in pharmaceutical chemistry from the University of California, San Francisco Medical Center, and did postdoctoral work (1968) at Pomona College, Claremont, California.
Content
About the Series -- Preface -- 1. Theories of Drug Action -- I. Evolution of Concepts of Drug-Receptor Interaction -- II. Occupancy Theory -- III. Rate Theory -- IV. Induced-Fit Theory: Allosteric Site and Cooperative Effect -- V. Macromolecular Perturbation Theory -- VI. The Second Messenger Concept -- VII. Active-Site-Directed Irreversible Inhibitors -- VIII. Mechanism- and Pharmacophore-Based Drug Design -- References -- 2. Improvement of Therapeutic Agents by Molecular Modification -- I. Modification of the Absorption of Drugs -- II. Optimization of Time Course and Distribution by Chemical Modification -- III. Modification of the Intrinsic Pharmacological Activity -- IV. Minimization of Biodegradation of Drugs -- V. Improvement of Acceptability by Chemical Modification -- References -- 3. Quantitative Structure-Activity Relationship -- I. Dose-Response Curve and Quantitative Measurement of Biological Activity -- II. Kinetics Versus Thermodynamics -- III. Structure-Acidity-Solubility Relationship -- IV. Multiple Regression Analysis and Numerical Presentation of Physicochemical Parameters -- V. QSAR of Convulsants, Anticonvulsants, and Depressants -- VI. QSAR of Narcotic Analgetics -- VII. QSAR of Antihistamines and Anticholinergics -- VIII. QSAR of Stereoisomers -- References -- 4. Ribonucleotide Reductase Inhibitors as Antiviral and Anticancer Agents -- I. Ribonucleotide Reductase (Ribonucleoside Diphosphate Reductase) as a Biochemical Target -- II. Inhibitors of RR -- References -- 5. Chemical Structure and Side Effects -- I. Extrapyramidal Syndrome -- II. Bone Marrow Depression and Blood Dyscrasias -- III. Hepatotoxicity -- IV. Nephrotoxicity -- V. Ototoxicity -- VI. Skin Sensitization and Drug-Induced Eosinophilia 281 VII. Glaucoma and Cataracts -- VIII. Carcinogenicity of Anticancer Drugs -- References -- Appendix -- Index.
